Mengzheng Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mengzheng Guo has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Dexian Zhi
Tianjin Key Laboratory of Food and Biotechnology, School of Biotechnology and Food Science, Tianjin University of Commerce, Tianjin 300134, China
1 shared publication - Hui Zhao
State Experimental and Training Centre of Food and Drug School of Biotechnology and Food Science Tianjin Key Laboratory of Food and Biotechnology Tianjin University of Commerce 300134 Tianjin China
1 shared publication Liang Bai
Tianjin Key Laboratory of Food and Biotechnology, School of Biotechnology and Food Science, Tianjin University of Commerce, Tianjin 300134, China
1 shared publication- Lianying Fang
Institute of Radiation Medicine, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China
1 shared publication - Liwen Wang
College of Food Science and Technology, Hebei Agricultural University, Baoding 071000, China
1 shared publication - Qiang Liu
Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2016
- Published by Wiley in BioMed Research International
- Vol. 2016, 1-10
Dietary Flavonoid Hyperoside Induces Apoptosis of Activated Human LX-2 Hepatic Stellate Cell by Suppressing Canonical NF-κB Signaling
Hyperoside, an active compound found in plants of the generaHypericumandCrataegus, is reported to exhibit antioxidant, anticancer, and anti-inflammatory activities. Induction of hepatic stellate cell (HSC) apoptosis is recognized as a promising strategy for attenuation of hepatic fibrosis. In this study, we investigated whether hyperoside treatment can exert antifibrotic effects in human LX-2 hepatic stellate cells. We found that hyperoside induced apoptosis in LX-2 cells and decreased levels ofα-smooth muscle actin (α-SMA), type I collagen, and intracellular reactive oxygen species (ROS). Remarkably, hyperoside also inhibited the DNA-binding activity of the transcription factor NF-κB and altered expression levels of NF-κB-regulated genes related to apoptosis, including proapoptotic genesBcl-Xs,DR4,Fas, andFasLand anti-apoptotic genesA20,c-IAP1,Bcl-, andRIP1. Our results suggest that hyperoside may have potential as a therapeutic agent for the treatment of liver fibrosis.- 1 January 2016
- Published by Wiley in BioMed Research International
- Vol. 2016, 1-10
Open AccessDietary Flavonoid Hyperoside Induces Apoptosis of Activated Human LX-2 Hepatic Stellate Cell by Suppressing Canonical NF-κB Signaling
Hyperoside, an active compound found in plants of the generaHypericumandCrataegus, is reported to exhibit antioxidant, anticancer, and anti-inflammatory activities. Induction of hepatic stellate cell (HSC) apoptosis is recognized as a promising strategy for attenuation of hepatic fibrosis. In this study, we investigated whether hyperoside treatment can exert antifibrotic effects in human LX-2 hepatic stellate cells. We found that hyperoside induced apoptosis in LX-2 cells and decreased levels ofα-smooth muscle actin (α-SMA), type I collagen, and intracellular reactive oxygen species (ROS). Remarkably, hyperoside also inhibited the DNA-binding activity of the transcription factor NF-κB and altered expression levels of NF-κB-regulated genes related to apoptosis, including proapoptotic genesBcl-Xs,DR4,Fas, andFasLand anti-apoptotic genesA20,c-IAP1,Bcl-, andRIP1. Our results suggest that hyperoside may have potential as a therapeutic agent for the treatment of liver fibrosis.